LRRC23 Inhibitors
Chemical inhibitors of LRRC23 can modulate its activity through a variety of mechanisms by targeting different signaling pathways and enzymes that are either directly or indirectly involved in its regulation. Staurosporine is a broad-spectrum protein kinase inhibitor that can impede the phosphorylation of LRRC23, as kinases are essential for such post-translational modifications that dictate the protein's activity. Similarly, Bisindolylmaleimide I and Gö 6983, both inhibitors of protein kinase C (PKC), can disrupt the signaling cascades that might be crucial for the functional activity of LRRC23, thereby attenuating its activity. Inhibition of Src family kinases by PP2 is another angle through which the regulation of LRRC23 can be affected, as Src kinases often play roles in various cellular processes, including those that may activate LRRC23.
Distinct from these, the PI3K inhibitors LY294002 and Wortmannin can shut down the PI3K-dependent pathways, potentially leading to a decrease in LRRC23 activity if it is part of such a pathway. On the other hand, Rapamycin acts on the mTOR pathway, which, if involved in the regulation of LRRC23, would result in the inhibition of its activity due to the blockade of mTOR signaling. The MAPK pathway inhibitors U0126 and PD98059 target MEK, upstream of ERK, which, when inhibited, would prevent the downstream effects on proteins such as LRRC23 if they are regulated within this pathway. SB203580's inhibition of p38 MAPK and SP600125's inhibition of JNK represent additional mechanisms by which LRRC23 activity can be inhibited, assuming involvement in these specific pathways. Lastly, Y-27632's inhibition of ROCK provides another potential route for the regulation of LRRC23, demonstrating the complexity and interconnectivity of the signaling networks that can govern the function of this protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Protein kinases are responsible for phosphorylating LRRC23, which is a post-translational modification that can regulate protein activity. By inhibiting the kinases that phosphorylate LRRC23, Staurosporine can inhibit the functionality of LRRC23. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K). If LRRC23 is part of a PI3K-dependent signaling pathway, inhibition by LY294002 would result in reduced PI3K activity, which would inhibit LRRC23 function as a result of diminished signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. As with LY294002, if LRRC23's function is mediated through PI3K signaling pathways, Wortmannin would inhibit the activity of LRRC23 by inhibiting PI3K and thus preventing downstream signaling that would normally activate LRRC23. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Inhibition of mTOR can result in the inhibition of downstream proteins that are regulated by mTOR signaling. If LRRC23 is downstream of mTOR, then Rapamycin would inhibit LRRC23 by inhibiting mTOR. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. As MEK is inhibited, the phosphorylation and activation of ERK are also inhibited. If LRRC23 is regulated through the MAPK pathway, then U0126 would functionally inhibit LRRC23. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If LRRC23 operates within the p38 MAPK signaling pathway, then inhibition of p38 MAPK by SB203580 would lead to inhibition of LRRC23 due to reduced signaling through this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. If LRRC23 is involved in a JNK signaling pathway, inhibition of JNK by SP600125 would lead to functional inhibition of LRRC23 as a result of decreased JNK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK1/2, enzymes upstream of ERK in the MAPK pathway. If LRRC23 is regulated through this pathway, inhibition of MEK1/2 by PD98059 would lead to functional inhibition of LRRC23. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a protein kinase C (PKC) inhibitor. If LRRC23 is modulated by PKC as part of its signaling cascade, inhibition of PKC would lead to functional inhibition of LRRC23. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Gö 6983 is a broad-spectrum PKC inhibitor. Similar to Bisindolylmaleimide I, if PKC signaling influences LRRC23 activity, Gö 6983 would inhibit LRRC23 by inhibiting PKC and thus preventing activation of LRRC23. | ||||||